

# 江苏省财政厅 文件 江苏省科学技术厅

苏财教〔2019〕119号

---

## 江苏省财政厅 江苏省科学技术厅 关于下达2019年省级重点研发计划专项资金 (社会发展)的通知

有关设区市、县(市)财政局、科技局，省有关单位：

为深入贯彻落实高质量发展要求和“十三五”省科技创新规划，加快重大技术突破和高技术攀升，提升关键领域自主创新水平和重点产业科技支撑能力，经研究，现将2019年省级重点研发计划专项资金(社会发展)下达给你们，相应增列2019年度“应用技术与开发”(政府收支分类科目2060402)预算支出指标。本次下达资金主要用于支持社会发展领域的关键共性技术突破、集成创新与应用示范类项目。

请你们严格按照《江苏省重点研发计划专项资金管理办法（暂行）》（苏财规〔2017〕23号）和省科技计划管理的有关规定，加强项目的组织协调和实施管理，确保经费专款专用，保证项目顺利实施。省科技厅将会同有关部门组织专家开展绩效评价，并将作为以后年度申报的重要依据。

- 附件： 1. 2019年省级重点研发计划专项资金（社会发展）  
分配表
2. 2019年省级重点研发计划专项资金（社会发展）  
项目表



---

江苏省财政厅办公室

2019年9月29日印发

---

## 2019 年省级重点研发计划专项资金（社会发展）项目表

经费单位：万元

项目编号	BE2019711	主管部门	东南大学	起止时间	2019.07-2022.06	项目负责人	柴人杰	
项目名称	通过基因治疗促进内耳干细胞再生听觉毛细胞重建听觉功能的研究			其 中	总经费	100	本年度省拨款	50
承担单位一	东南大学				省拨款	50		
承担单位二					主管部门匹配	0		
依托单位	南京鼓楼医院 杭州荣泽生物科技有限公司				自筹经费	50		
主要内容和考核指标	<p>优化改造新型 AAV 提高对小鼠内耳干细胞的感染效率从而建立针对小鼠内耳干细胞的 AAV 介导的基因治疗系统；研究 Wnt, Notch, Shh, Hippo 等信号通路对内耳干细胞的增殖, 分化的调控机制；研究通过多种信号通路协同调控促进内耳干细胞再生毛细胞的作用和机制。建立基因治疗策略对恢复听力的有效性和效率的评价体系；通过新型 AAV 介导的基因治疗在内耳干细胞中调控多种信号通路促进其再生具有功能的毛细胞, 以部分恢复听力。1、阐明 Wnt 等多种信号通路对内耳干细胞再生毛细胞的协同调控作用；建立基因治疗策略对恢复听力的有效性和效率的评价体系, 通过 AAV 在内耳干细胞中调控多基因促进其再生有功能的毛细胞 达到耳蜗结构和功能的部分修复, 从而部分恢复听觉功能；2、在国际权威期刊上发表研究论文 10-15 篇, 申请专利 2~3 项, 编写听觉器官再生相关著作 1 部；培养 6 名博士, 6 名硕士。</p>							
备注								

项目编号	BE2019712	主管部门	东南大学	起止时间	2019.07-2022.06	项目负责人	陈平圣	
项目名称	基于深度学习的人工智能膜性肾病病理诊断系统的建立和应用研究			其 中	总经费	100	本年度省拨款	50
承担单位一	东南大学				省拨款	50		
承担单位二					主管部门匹配	0		
依托单位	江苏嘉纳宝医疗科技有限公司				自筹经费	50		
主要内容和考核指标	<p>筛选诊断明确、病变典型的切片进行数字化扫描, 完成全切片数字化图像制作, 筛选免疫荧光和电镜图片备用。医生团队按光镜、电镜、免疫荧光 3 个系列进行病变标注。软件研发团队对数据进行预处理, 然后按照 6 : 2 : 2 的比例分为训练集、验证集和测试集。软件研发团队运用多个在图像识别分类上有效的基本模型来对系统进行基准训练。最后通过受试者工作特征曲线客观评价算法的性能。1、PAS、PASM 图片训练集、验证集和测试集 2 套, ≥400 例 天狼星红染色图片训练集、验证集和测试集 1 套, ≥400 例 人工智能膜性肾病病理诊断系统软件 1 套, 人机诊断符合率 ≥90% 2、申请发明专利 1 项；发表学术论文 3 篇；研究报告 1 份；软件著作权 1 项；诊断软件 1 套；训练集、验证集、测试集 5 套。3、培养研究生 3 名。</p>							
备注								

**E-mail**

**From**  Eileen Fitzgerald **Cc**  Dan Carrington  
**To**  Guozheng Wang **Bcc**  
**Subject** BHF Project Grant Application Outcome ref 30751 CRM:0056207

26 March 2014

Dear Dr Wang

**BHF Project Grant no. PG/14/19/30751**

"The role of circulating histones in the cardiac dysfunction of sepsis"

The above application was considered at the recent meeting of the Project Grants Committee. I am pleased to confirm we have awarded up to the sum of £143,240 for the work over 2 years and a breakdown of this sum is below. Please note the condition below that states the grant may not start until all ethical and governance approvals and licences are in place. Some comments on your application are below. These are for information only and we hope you will find them helpful.

A travel fund of £1,000 per year is available for applicants and staff named on the grant to present at or attend scientific meetings relevant to the grant. Further details are available here.

The award is subject to your acceptance of BHF's Standard Conditions and the following special conditions:

1. Please print out, complete and return an 'acceptance of grant' form within one month of today's date (original signatures only).
2. The grant may **not** begin until **all** regulatory research governance approvals are in place, eg university, ethics, MHRA, licenses etc. A copy of the ethical approval, if needed for the work and not included in the application, must be submitted to us before the grant starts.
3. For clinical trials and clinical studies that involve patients within the NHS, the principal investigator must:  
apply to have the study included in the UK Clinical Research Network Portfolio  
ensure the BHF grant reference number is recorded on the UK CRN Portfolio database  
upload recruitment data onto the UK CRN Portfolio database on a regular basis (monthly)  
keep information about the study on the UK CRN Portfolio database up to date (including information about extensions or study closure)
4. For clinical trials or clinical studies that involve recruitment and investigation/follow up of patients (rather than analysis of tissue samples only), you must submit Annual Reports.
5. Refer to Managing Your Grant for our requirements about reporting progress including relevant forms, evaluation through Researchfish and publishing your research.

08 July 2016

Dear Dr Wang,

**BHF Project Grant no. PG/16/65/32313**

“The mechanisms of extracellular histone-induced immunothrombosis and its roles in microvascular circulatory failure during critical illnesses”

The above application was considered at the recent meeting of the Project Grants Committee. I am pleased to confirm we have awarded up to the sum of £243,401 for the work over 3 years and a breakdown of this sum is below.

Please note the condition below that states the grant may not start until all ethical and governance approvals and licences are in place.

A travel fund of £1,000 per year is available for applicants and staff named on the grant to present at or attend scientific meetings relevant to the grant. Further details are available [here](#).

The award is subject to your acceptance of [BHF's Standard Conditions](#) and the following special conditions:

1. Please print out, complete and return an '[acceptance of grant](#)' form within one month of today's date (original signatures only).
2. The grant may **not** begin until **all** regulatory research governance approvals are in place, eg university, ethics, MHRA, licenses etc. A copy of the ethical approval, if needed for the work and not included in the application, must be submitted to us before the grant starts.
3. It is noted Dr Y Alhanidi is already funded on another BHF grant (PG/14/19/30751). He must complete this work before starting work on the new grant.
4. For clinical trials and clinical studies that involve patients within the NHS, the principal investigator must:
  - apply to have the study included in the [UK Clinical Research Network Portfolio](#)
  - ensure the BHF grant reference number is recorded on the UK CRN Portfolio database
  - upload recruitment data onto the UK CRN Portfolio database on a regular basis (monthly)
  - keep information about the study on the UK CRN Portfolio database up to date (including information about extensions or study closure)
5. For clinical trials or clinical studies that involve recruitment and investigation/follow up of patients (rather than analysis of tissue samples only), you must submit [Annual Reports](#).

**From:** Wang, Guozheng  
**Sent:** 09 August 2016 14:36  
**To:** Stephens, Dale  
**Cc:** Beckett, Sharon  
**Subject:** RE: BHF Application Outcome CRM:0001026 Ref:32313

Dear Dale,

Could you please assign a cost centre for the grant?

G

---

**From:** Wang, Guozheng  
**Sent:** 22 July 2016 15:35  
**To:** Stephens, Dale  
**Subject:** FW: BHF Application Outcome CRM:0001026 Ref:32313

Dear Dale,

This is the BHF grant.

Have a nice weekend

G

---

**From:** Laura Lucas [lucasla@bhf.org.uk]  
**Sent:** 08 July 2016 14:00  
**To:** Wang, Guozheng  
**Cc:** Burton, Clare  
**Subject:** BHF Application Outcome CRM:0001026 Ref:32313

08 July 2016

Dear Dr Wang,

**BHF Project Grant no. PG/16/65/32313**

“The mechanisms of extracellular histone-induced immunothrombosis and its roles in microvascular circulatory failure during critical illnesses”

The above application was considered at the recent meeting of the Project Grants Committee. I am pleased to confirm we have awarded up to the sum of £243,401 for the work over 3 years and a breakdown of this sum is below.

Please note the condition below that states the grant may not start until all ethical and governance approvals and licences are in place.

A travel fund of £1,000 per year is available for applicants and staff named on the grant to present at or attend scientific meetings relevant to the grant. Further details are available [here](#).